In mouse tumor models, CCR2 blockade depletes inflammatory resident monocytes and macrophages from the primary tumor and premetastatic liver, resulting in enhanced antitumor immunity, decreased tumor growth, and reduced metastasis (Sanford et al., 2013). This evidence concerns the gene CCR2 and neoplasm.